Assessing the market for a C. difficile vaccine

Assessing the market for a C. difficile vaccine


Our client wanted to see an accurate picture of how C. difficile infections were dealt with in the UK, Germany and Spain. They wanted to decide whether to introduce their new product into vaccine schedules or as a drug by determining the decision pathways and funding implications for both options.

The right stakeholders, the right channels

Due to our previous experience in this arena, Lightspeed All Global knows that different types of Payers and stakeholders make decisions on vaccines and drugs. We arranged our research accordingly, and succeeded in carrying out in depth telephone interviews with senior advisors across the geographies, including top advisors to advisory committees and government health departments.

The right result

The client commented:

”The fact that Lightspeed All Global identified the need right from the start for a different type of Payer/influencer allowed us to quickly find the right respondents to target and gave us incredible access to this limited universe of stakeholders.”